Sarepta Therapeutics
SRPT
366 hedge funds and large institutions have $1.42B invested in Sarepta Therapeutics in 2025 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 163 increasing their positions, 89 reducing their positions, and 128 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 163 | Existing positions reduced: 89
65% more call options, than puts
Call options by funds: $132M | Put options by funds: $79.5M
5.31% less ownership
Funds ownership: 89.55% → 84.24% (-5.3%)
16% less funds holding
Funds holding: 434 → 366 (-68)
25% less capital inflows, than outflows
Capital inflows: $1.29B | Capital outflows: $1.71B
51% less first-time investments, than exits
New positions opened: 63 | Existing positions closed: 128
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$191M |
| 2 |
BlackRock
New York
|
+$94.2M |
| 3 |
Two Sigma Advisers
New York
|
+$72.9M |
| 4 |
Two Sigma Investments
New York
|
+$68.7M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$66.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$365M |
| 2 |
Avoro Capital Advisors
New York
|
-$171M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
-$149M |
| 4 |
Janus Henderson Group
London,
|
-$142M |
| 5 |
EcoR1 Capital
San Francisco,
California
|
-$82.5M |
SRPT Hedge Fund Activity: Q2 2025 in Review
366 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2025, worth a combined $1.42B — down 75% from $5.57B a quarter earlier.
Sellers outnumbered buyers: 128 funds closed out of SRPT and 63 opened new positions — a net loss of 65 holders — while 89 trimmed existing stakes and 163 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $191M. The largest seller was Capital International Investors, cutting an estimated $365M.
- 366 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2025, down from 434 in Q1 2025.
- Funds reported $1.42B of Sarepta Therapeutics stock for Q2 2025, down 75% quarter-over-quarter.
- 63 funds opened new Sarepta Therapeutics positions in Q2 2025 and 128 closed out, a net change of -65 holders.
- The largest Sarepta Therapeutics buyer in Q2 2025 was D.E. Shaw & Co, an estimated $191M added.
- The largest Sarepta Therapeutics seller in Q2 2025 was Capital International Investors, an estimated $365M sold.
Based on aggregated 13F filings for Q2 2025.